| 0.4523 0 (0%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Lucira Health, Inc. is a medical technology enterprise dedicated to the development and commercialization of diagnostic test kits for infectious diseases. The company has innovated a platform capable of providing molecular testing capabilities. Among its current product offerings is the LUCIRA COVID-19 All-In-One Test Kit, and it is also progressing with the development of diagnostic solutions for influenza A and B viruses. Lucira Health holds a patent license agreement with Eiken Chemical Co., Ltd., alongside technical and manufacturing service agreements with Jabil, Inc. and Jabil MSA, respectively. Founded in 2013, the company operated as DiAssess Inc. until January 2020 when it rebranded to Lucira Health, Inc. Its main offices are situated in Emeryville, California.
Fri, 11 Jul 2025
Profusa (PFSA) Stock Price, News & Analysis - Stock Titan
Wed, 22 Feb 2023
Covid Test Maker Lucira (LHDX) Goes Bankrupt as Demand for Kits Wanes - Bloomberg.com
Wed, 04 Jan 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Tue, 03 Jan 2023
Why Lucira Health (LHDX) Stock Up 400% Today? - InvestorPlace
Thu, 24 Mar 2022
Lucira Health's PCR-Quality At-Home COVID-19 Test Now Available Direct to Consumers in Canada - PR Newswire Canada
Mon, 20 Dec 2021
TOP RANKED ROSEN LAW FIRM Encourages Lucira Health, Inc. Investors with Losses to Inquire About Class Action Investigation - LHDX - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|